Intervacc receives order for Strangvac, a vaccine against the equine disease strangles, from the Dechra Pharmaceuticals PLC Group for launch in selected European countries

Stockholm, July 20th 2022 - Intervacc AB (publ) announces today that the company has received an order for the equivalent of approximately SEK 3 million from Dechra. The order concerns the delivery of Strangvac®, a vaccine against the highly contagious and serious infectious disease equine strangles, which is endemic across Europe. The order, which contains vaccine vials for regions including the UK, Germany and France, is for delivery during July 2022 and used for launch in selected European countries.

"This order from our distribution partner Dechra, will facilitate the launch of Strangvac® in the first European countries outside Scandinavia," says Andreas Andersson, CEO of Intervacc. *"Since the approval of Strangvac® for use in Europe and the UK, we together with Dechra, have had positive meetings with hundreds of leading equine veterinarians and Key Opinion Leaders around Europe to discuss how Strangvac® is suitable for intramuscular administration and can be used in synergy with current preventative measures to improve the health of horses."* Andreas continues, *"As Strangvac® becomes available for sale in a specific country, we will expand our information and education campaign to reach a wider range of veterinarians and help a growing number of horses in their care."*

For more information please contact:

Andreas Andersson, CEO
Phone: +46-8-120 10 601, cell +46-73-335 99 70
E-mail: andreas.andersson@intervacc.com

This information is information that Intervacc AB (publ) is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication, through the agency of the contact person set out above on July 20, 2022.

About Intervacc

Intervacc AB is a Swedish company within animal health developing safe, effective vaccines for animals. The Company's vaccine and vaccine candidates are based on several years of research at Karolinska Institutet and Swedish University of Agricultural Research where the foundation was laid for the Company´s research and development work. The Intervacc share has been listed on the Nasdaq First North Growth Market since April 2017 with Eminova Fondkommission AB, adviser@eminova.se, +46 (0)8–684 211 10 as Certified Adviser.

About Dechra

Dechra is a global specialist veterinary pharmaceuticals and related products business. Dechra's expertise is in the development, manufacture marketing and sales of high quality products exclusively for veterinarians worldwide. Dechra's business is unique as the majority of its products are used to treat medical conditions for which there is no other effective solution or have a clinical or dosing advantage over competitor products. For more information, please visit: www.dechra.com
Stock Code: Full Listing (Pharmaceuticals): DPH , LEI: 213800J4UVB5OWG8VX82

About equine strangles

Equine strangles, caused by *Streptococcus equi*, is the most frequently diagnosed infectious disease of horses, and affects horses all over the world with one exception Iceland where the import of horses is prohibited. *Streptococcus equi* invades the lymph nodes of head and neck, causing them to swell and form abscesses that can literally strangle, in around 2% of cases, the horse to death. Some of the horses that recover from strangles remain persistently infected. These apparently healthy animals shed bacteria into the environment and spread the disease to other horses with which they come into contact.

Contact information for Certified Adviser

Eminova Fondkommission AB
E-mail: adviser@eminova.se, Phone: +46 (0)8 – 684 211 10

Date Created
2022-07-20